Navigation Links
Verenium Reports Financial Results for the Third Quarter 2010
Date:11/9/2010

tates and China;
  • Renewed and extended the Company's successful joint marketing agreement with Alfa Laval for Purifine® PLC for five years; and
  • Licensed a new lipase enzyme for use in the production of edible oil products to Bunge Oils, Inc.

  • Manufacturing

  • Hired Kevin Bracken as Vice President of Manufacturing to lead the optimization and expansion of manufacturing capabilities; and
  • Acquired control of additional fermentation capacity at Fermic, the Company's contract manufacturing facility in Mexico City.

  • Corporate/Financial:

  • Completed the sale of the Company's cellulosic biofuels business to BP, including facilities in Jennings, LA and San Diego, CA for net cash proceeds of $95.4 million;
  • Repurchased $21 million in principal amount of 8% and 5.5% Notes, eliminating all outstanding 8% Notes;
  • Appointed Alexander Fitzpatrick as Senior Vice President and General Counsel, further building out the senior management team;
  • Ended the quarter with unrestricted cash and cash equivalents totaling $89 million;
  • Increased total product revenue by 11% and 16% for the three and nine months ended September 30, 2010 respectively, when compared to the same periods in 2009;
  • Improved revenue mix from increasing sales of Company's newer enzymes including Fuelzyme, Xylathin, Veretase and Purifine; and
  • Increased product gross margin dollars by 17% and 20% for the three and nine months ended September 30, 2010 as compared to the same periods in 2009.

  • "The third quarter was an important quarter for Verenium in terms of demonstrating the growth potential of our enzyme products in all our industry areas," said James E. Levine, Executive Vice President and Chief Financial Officer.  "With the close of the BP transaction, we now have the financial flexibility to invest in the company and grow our enzymes business."

    Financial ResultsIn the commenta
    '/>"/>

    SOURCE Verenium Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Verenium to Present at Jefferies 10th Global Clean Technology Conference
    2. Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement
    3. Verenium Announces Regulatory Approval for Purifine® PLC in China
    4. Verenium Launches DELTAZYM® GA L-E5 Enzyme for Fuel Ethanol Production
    5. Verenium Appoints Kevin Bracken Vice President of Manufacturing
    6. Verenium Announces Proposed Public Offering of Common Stock
    7. Verenium 1:12 Reverse Stock Split Takes Effect
    8. Verenium Announces Reverse Stock Split to Take Effect September 9
    9. BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
    10. Verenium Completes Amendment to 8% Senior Convertible Notes
    11. Verenium Announces Organizational Changes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2014)... July 30, 2014 July 30, 2014. ... a biotechnology firm that provides DNA-based authentication and security ... Ph.D. Vice President of Life Sciences, a newly created ... , Dr. Hogan will lead APDN’s drive to build ... with biotech and healthcare customers, provide guidance to APDN’s ...
    (Date:7/30/2014)... , July 30, 2014  Dyadic International, Inc. ... whose patented and proprietary technologies are used to ... proteins for the bioenergy, bio-based chemical, biopharmaceutical and ... Thomas "Tom" Dubinski as Vice President and Chief ... the financial and information technology operations for Dyadic ...
    (Date:7/30/2014)... Edwardsville, IL (PRWEB) July 30, 2014 ... Dr. Arun Athmanathan will present his findings on ... of Energy conference this week in Washington, D.C. ... Department of Energy conference is a testament to ... Director John Caupert said. “Thanks to the foresight ...
    (Date:7/30/2014)... 30, 2014 LayerBio, Inc., an MIT ... its first round of seed financing from friends and ... efforts to develop a novel sustained-release product for ophthalmology. ... investors and their commitment to this important work," said ... is one of many areas in which innovations in ...
    Breaking Biology Technology:Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
    ... , VANCOUVER , July 28 ... ANP) ("Angiotech") and partner Athersys, Inc. (NASDAQ: ATHX) ... trial of MultiStem(R), its allogeneic cell therapy product, ... more commonly referred to as a heart attack. ...
    ... July 28 VIASPACE Inc. (OTC Bulletin Board: ... a low-carbon, renewable biomass crop, reported that Chief Executive Dr. ... Third Annual World Congress of Industrial Biotechnology held in ... than 500 business executives, industry leaders, technical experts, government officials ...
    ... July 27 ITelagen, a leading provider of electronic health record ... Asthma Associates of Northern California , San Jose, CA ... includes hosting of patient data in ITelagen,s SAS-70 Type II certified datacenter ... , , ...
    Cached Biology Technology:Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 2Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 3Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 4Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 5Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 6Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 7Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 8Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 9VIASPACE CEO Discusses Giant King Grass at Industrial Biotechnology Congress in China 2VIASPACE CEO Discusses Giant King Grass at Industrial Biotechnology Congress in China 3VIASPACE CEO Discusses Giant King Grass at Industrial Biotechnology Congress in China 4Allergy and Asthma Associates Selects ITelagen for Hosting and Management of EHR 2Allergy and Asthma Associates Selects ITelagen for Hosting and Management of EHR 3
    (Date:7/30/2014)... Everybody knows the shortest distance between two points is ... that sperm have been taking the familiar axiom to ... usually thought to be intense, with each racing for ... in some species, sperm form cooperative groups that allow ... , A new study, conducted by Heidi Fisher, ...
    (Date:7/30/2014)... Sciences Institute (SALSI), a joint venture between The University ... of Texas Health Science Center at San Antonio, has ... The winners, Emily Boice from UTSA and Lei Huang ... their project titled, "Novel engineered ferritins for tracking and ... and Huang,s research is focused on finding a treatment ...
    (Date:7/30/2014)... Laboratory has received a pledge of $1 million from ... the Laboratory,s new Neurobehavioral Biometry Center. , ... will enable the Laboratory to develop a greater breadth ... ultimate goal of accelerating the pace of research to ... as a premier resource for the Laboratory and its ...
    Breaking Biology News(10 mins):When cooperation counts 2When cooperation counts 3Rossi Foundation pledges $1M for JAX neurobehavioral research center 2
    ... Hopkins researchers say they have discovered a cause-and-effect ... schizophrenia previously believed to be independent of one ... to develop better drugs to treat the cognitive ... illnesses. ,Researchers have long studied the role ...
    ... 2012 The University of Miami (UM) Rosenstiel School of ... 2012-2013 Alumni Awards. The grantees were selected by a ... more than $11,000 in funds. , "We received 30 applications ... biology to meteorology," said Laura Bracken Chaibongsai, Alumni & Outreach ...
    ... place certain types of living cells on a microscope slide, ... and assemble themselves into a simple, if primitive tissue. A ... and then some, about the mechanical structure and behavior of ... Proceedings of the National Academy of Sciences , chemical ...
    Cached Biology News:Johns Hopkins researchers link 2 biological risk factors for schizophrenia 2Recipients of UM Rosenstiel School's 2012-2013 Alumni Awards announced 2Force of nature: Defining the mechanical mechanisms in living cells 2Force of nature: Defining the mechanical mechanisms in living cells 3Force of nature: Defining the mechanical mechanisms in living cells 4
    ... Silver Staining Kit, 1. Select from ... and peptides on denaturing, native, and ... reproducibility with precast gels, buffer strips, ... to that of radioisotopes with ready-to-use ...
    Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
    ... Anti-Major DNA-binding protein(DBP). Protein ... NP_001343 ELISA titre using ... Suggested conditions for Western Blot: ... buffer, and HRP conjugated anti-Rabbit IgG should ...
    ... GI Number: 4503277 Accession Number: ... FUNCTION: Supplies the nucleotide substrate for ... H 2 O = dUMP + ... Belongs to the Diseases: Benign Tumor; ...
    Biology Products: